Molecular characterization of a precision-cut rat liver slice model for the evaluation of antifibrotic compounds.

Precision-cut liver tissue slice (PCLS) contains all major cell types of the liver parenchyma and preserves the original cell-cell and cell-matrix contacts. It represents a promising ex vivo model to study liver fibrosis and test the antifibrotic effect of experimental compounds in a physiological environment. In this study using RNA sequencing, we demonstrated that various pathways functionally related to fibrotic mechanisms were dysregulated in PCLSs derived from rats subjected to bile duct ligation. The activin receptor-like kinase-5 (Alk5) inhibitor SB525334, nintedanib, and sorafenib each reversed a subset of genes dysregulated in fibrotic PCLSs, and of those genes we identified 608 genes whose expression was reversed by all three compounds. These genes define a molecular signature characterizing many aspects of liver fibrosis pathology and its attenuation in the model. A panel of 12 genes and 4 secreted biomarkers including procollagen I, hyaluronic acid (HA), insulin-like growth factor binding protein 5 (IGFBP5), and WNT1-inducible signaling pathway protein 1 (WISP1) were further validated as efficacy end points for the evaluation of antifibrotic activity of experimental compounds. Finally, we showed that blockade of αV-integrins with a small molecule inhibitor attenuated the fibrotic phenotype in the model. Overall, our results suggest that the rat fibrotic PCLS model may represent a valuable system for target validation and determining the efficacy of experimental compounds. NEW & NOTEWORTHY We investigated the antifibrotic activity of three compounds, the activin receptor-like kinase-5 (Alk5) inhibitor SB525334, nintedanib, and sorafenib, in a rat fibrotic precision-cut liver tissue slice model using RNA sequencing analysis. A panel of 12 genes and 4 secreted biomarkers including procollagen I, hyaluronic acid (HA), insulin-like growth factor binding protein 5 (IGFBP5), and WNT1-inducible signaling pathway protein 1 (WISP1) were then established as efficacy end points to validate the antifibrotic activity of the αV-integrin inhibitor CWHM12. This study demonstrated the value of the rat fibrotic PCLS model for the evaluation of antifibrotic drugs.

[1]  M. Lindner,et al.  Differential effects of Nintedanib and Pirfenidone on lung alveolar epithelial cell function in ex vivo murine and human lung tissue cultures of pulmonary fibrosis , 2018, Respiratory Research.

[2]  S. Ricard-Blum,et al.  Molecular and tissue alterations of collagens in fibrosis. , 2018, Matrix biology : journal of the International Society for Matrix Biology.

[3]  D. Schuppan,et al.  Liver fibrosis: Direct antifibrotic agents and targeted therapies. , 2018, Matrix biology : journal of the International Society for Matrix Biology.

[4]  C. Newby,et al.  A model of human lung fibrogenesis for the assessment of anti-fibrotic strategies in idiopathic pulmonary fibrosis , 2018, Scientific Reports.

[5]  Astrid Gall,et al.  Ensembl 2018 , 2017, Nucleic Acids Res..

[6]  M. Mack.  Inflammation and fibrosis. , 2017, Matrix biology : journal of the International Society for Matrix Biology.

[7]  G. Raghu.  Pharmacotherapy for idiopathic pulmonary fibrosis: current landscape and future potential , 2017, European Respiratory Review.

[8]  M. Bazzo,et al.  Circulating levels of pentraxin-3 (PTX3) in patients with liver cirrhosis. , 2017, Annals of hepatology.

[9]  L. Richeldi,et al.  Investigational drugs for idiopathic pulmonary fibrosis , 2017, Expert opinion on investigational drugs.

[10]  A. Günther,et al.  Senolytic drugs target alveolar epithelial cell function and attenuate experimental lung fibrosis ex vivo , 2017, European Respiratory Journal.

[11]  K. Tatsumi,et al.  Pirfenidone may revert the epithelial-to-mesenchymal transition in human lung adenocarcinoma. , 2017, Oncology letters.

[12]  A. Walch,et al.  A Novel Antifibrotic Mechanism of Nintedanib and Pirfenidone. Inhibition of Collagen Fibril Assembly , 2017, American journal of respiratory cell and molecular biology.

[13]  M. Lindner,et al.  An ex vivo model to induce early fibrosis-like changes in human precision-cut lung slices. , 2017, American journal of physiology. Lung cellular and molecular physiology.

[14]  R. Chambers,et al.  An Official American Thoracic Society Workshop Report: Use of Animal Models for the Preclinical Assessment of Potential Therapies for Pulmonary Fibrosis , 2017, American journal of respiratory cell and molecular biology.

[15]  G. Storm,et al.  Tyrosine kinase inhibitor BIBF1120 ameliorates inflammation, angiogenesis and fibrosis in CCl4-induced liver fibrogenesis mouse model , 2017, Scientific Reports.

[16]  W. Yantasee,et al.  Oxidative stress in cancer and fibrosis: Opportunity for therapeutic intervention with antioxidant compounds, enzymes, and nanoparticles , 2016, Redox biology.

[17]  J. Connolly,et al.  Multiplex Serum Protein Analysis Identifies Novel Biomarkers of Advanced Fibrosis in Patients with Chronic Liver Disease with the Potential to Improve Diagnostic Accuracy of Established Biomarkers , 2016, PloS one.

[18]  C. Liu,et al.  Sorafenib Inhibits Renal Fibrosis Induced by Unilateral Ureteral Obstruction via Inhibition of Macrophage Infiltration , 2016, Cellular Physiology and Biochemistry.

[19]  N. Henderson,et al.  αv integrins: key regulators of tissue fibrosis , 2016, Cell and Tissue Research.

[20]  G. Jenkins,et al.  Caffeine inhibits TGFβ activation in epithelial cells, interrupts fibroblast responses to TGFβ, and reduces established fibrosis in ex vivo precision-cut lung slices , 2016, Thorax.

[21]  H. Baarsma,et al.  WISP1 mediates IL-6-dependent proliferation in primary human lung fibroblasts , 2016, Scientific Reports.

[22]  M. Neuman,et al.  Hyaluronic acid as a non-invasive biomarker of liver fibrosis. , 2016, Clinical biochemistry.

[23]  C. A. de la Motte,et al.  Hyaluronan's Role in Fibrosis: A Pathogenic Factor or a Passive Player? , 2015, BioMed research international.

[24]  M. Medvedovic,et al.  Fibrocytes Regulate Wilms Tumor 1–Positive Cell Accumulation in Severe Fibrotic Lung Disease , 2015, The Journal of Immunology.

[25]  S. Carr,et al.  The extracellular matrix: Tools and insights for the "omics" era. , 2015, Matrix biology : journal of the International Society for Matrix Biology.

[26]  Kuen-Feng Chen,et al.  Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition , 2015, Proceedings of the National Academy of Sciences.

[27]  F. Liu,et al.  Matricellular protein periostin contributes to hepatic inflammation and fibrosis. , 2015, The American journal of pathology.

[28]  Naftali Kaminski,et al.  A novel genomic signature with translational significance for human idiopathic pulmonary fibrosis. , 2015, American journal of respiratory cell and molecular biology.

[29]  Raphael Gottardo,et al.  Orchestrating high-throughput genomic analysis with Bioconductor , 2015, Nature Methods.

[30]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[31]  R. Kaarteenaho,et al.  Pharmacological treatment of idiopathic pulmonary fibrosis – preclinical and clinical studies of pirfenidone, nintedanib, and N-acetylcysteine , 2015, European clinical respiratory journal.

[32]  Madhusudhan Reddy,et al.  Developing an in vitro screening assay platform for evaluation of antifibrotic drugs using precision-cut liver slices , 2014, Fibrogenesis & tissue repair.

[33]  H. Forrester,et al.  Identification of a radiation sensitivity gene expression profile in primary fibroblasts derived from patients who developed radiotherapy-induced fibrosis. , 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[34]  Geny M. M. Groothuis,et al.  The Effect of Antifibrotic Drugs in Rat Precision-Cut Fibrotic Liver Slices , 2014, PloS one.

[35]  A. Tamori,et al.  Cytoglobin is expressed in hepatic stellate cells, but not in myofibroblasts, in normal and fibrotic human liver , 2014, Laboratory Investigation.

[36]  B. Grasl-Kraupp,et al.  Myofibroblasts are important contributors to human hepatocellular carcinoma: Evidence for tumor promotion by proteome profiling , 2013, Electrophoresis.

[37]  B. Karlan,et al.  A Collagen-Remodeling Gene Signature Regulated by TGF-β Signaling Is Associated with Metastasis and Poor Survival in Serous Ovarian Cancer , 2013, Clinical Cancer Research.

[38]  K. Tsuneyama,et al.  STAT3-mediated attenuation of CCl4-induced mouse liver fibrosis by the protein kinase inhibitor sorafenib. , 2013, Journal of autoimmunity.

[39]  T. Oury,et al.  Animal models of fibrotic lung disease. , 2013, American journal of respiratory cell and molecular biology.

[40]  D. Griggs,et al.  Selective αv integrin depletion identifies a core, targetable molecular pathway that regulates fibrosis across solid organs , 2013, Nature Medicine.

[41]  L. Xu,et al.  Sorafenib ameliorates bleomycin-induced pulmonary fibrosis: potential roles in the inhibition of epithelial–mesenchymal transition and fibroblast activation , 2013, Cell Death and Disease.

[42]  Hiroshi I. Suzuki,et al.  An Integrated Expression Profiling Reveals Target Genes of TGF-β and TNF-α Possibly Mediated by MicroRNAs in Lung Cancer Cells , 2013, PloS one.

[43]  B. Stefanovic,et al.  Role of cytokine receptor-like factor 1 in hepatic stellate cells and fibrosis. , 2012, World journal of hepatology.

[44]  M. Karsdal,et al.  Phosphodiesterase inhibition mediates matrix metalloproteinase activity and the level of collagen degradation fragments in a liver fibrosis ex vivo rat model , 2012, BMC Research Notes.

[45]  E. Puré,et al.  Fibroblast activation protein in remodeling tissues. , 2012, Current molecular medicine.

[46]  A. Hata,et al.  Targeting the TGFβ signalling pathway in disease , 2012, Nature Reviews Drug Discovery.

[47]  Y. Ngo,et al.  Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: proof of concept and first application in a large population. , 2012, Journal of hepatology.

[48]  S. Friedman,et al.  Antifibrotic Activity of Sorafenib in Experimental Hepatic Fibrosis: Refinement of Inhibitory Targets, Dosing, and Window of Efficacy In Vivo , 2012, Digestive Diseases and Sciences.

[49]  Jun Hu,et al.  OSA: a fast and accurate alignment tool for RNA-Seq , 2012, Bioinform..

[50]  M. Duncan,et al.  aV integrins and TGF-β-induced EMT: a circle of regulation , 2012, Journal of cellular and molecular medicine.

[51]  Davis J. McCarthy,et al.  Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation , 2012, Nucleic acids research.

[52]  B. Mahon,et al.  Biomarkers of the insulin-like growth factor pathway predict progression and outcome in lung cancer. , 2011, The Annals of thoracic surgery.

[53]  N. Frangogiannis,et al.  TGF-β signaling in fibrosis , 2011, Growth factors.

[54]  P. Olinga,et al.  Exposure of precision-cut rat liver slices to ethanol accelerates fibrogenesis. , 2010, American journal of physiology. Gastrointestinal and liver physiology.

[55]  A. Mukhopadhyay,et al.  Comparative proteomic analysis between normal skin and keloid scar , 2010, The British journal of dermatology.

[56]  Y. Ngo,et al.  Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest) , 2010, BMC gastroenterology.

[57]  P. Bosma,et al.  Insulin-like growth factor binding protein 5 enhances survival of LX2 human hepatic stellate cells , 2010, Fibrogenesis & tissue repair.

[58]  Colin N. Dewey,et al.  RNA-Seq gene expression estimation with read mapping uncertainty , 2009, Bioinform..

[59]  Davis J. McCarthy,et al.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..

[60]  W. Seeger,et al.  WNT1-inducible signaling protein-1 mediates pulmonary fibrosis in mice and is upregulated in humans with idiopathic pulmonary fibrosis. , 2009, The Journal of clinical investigation.

[61]  O. Gressner,et al.  Activation of hepatic stellate cells is associated with cytokine expression in thioacetamide-induced hepatic fibrosis in mice , 2008, Laboratory Investigation.

[62]  S. Friedman,et al.  Mechanisms of hepatic fibrogenesis. , 2008, Gastroenterology.

[63]  H. Kikkawa,et al.  Inhibition of activin receptor-like kinase 5 attenuates bleomycin-induced pulmonary fibrosis. , 2007, Experimental and molecular pathology.

[64]  A. Desmoulière,et al.  Specific activation of the different fibrogenic cells in rat cultured liver slices mimicking in vivo situations , 2007, Virchows Archiv.

[65]  J. Iredale.  Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. , 2007, The Journal of clinical investigation.

[66]  A. El-Karef,et al.  Deficiency of tenascin‐C attenuates liver fibrosis in immune‐mediated chronic hepatitis in mice , 2007, The Journal of pathology.

[67]  P. Olinga,et al.  Human liver slices as an in vitro model to study toxicity-induced hepatic stellate cell activation in a multicellular milieu. , 2006, Chemico-biological interactions.

[68]  A. Desmoulière,et al.  Effects of bile acids on biliary epithelial cell proliferation and portal fibroblast activation using rat liver slices , 2006, Laboratory Investigation.

[69]  P. Olinga,et al.  Precision-cut liver slices as a new model to study toxicity-induced hepatic stellate cell activation in a physiologic milieu. , 2005, Toxicological sciences : an official journal of the Society of Toxicology.

[70]  J. Gauthier,et al.  Inhibition of TGF‐β signaling by an ALK5 inhibitor protects rats from dimethylnitrosamine‐induced liver fibrosis , 2005 .

[71]  E. Fábrega,et al.  Osteoprotegerin and RANKL in alcoholic liver cirrhosis , 2005, Liver international : official journal of the International Association for the Study of the Liver.

[72]  A. Nicholson,et al.  Gene expression profiling reveals novel TGFβ targets in adult lung fibroblasts , 2004, Respiratory research.

[73]  D. Sheppard.  Roles of αv integrins in vascular biology and pulmonary pathology , 2004 .

[74]  Lisa M. D'Souza,et al.  Genome sequence of the Brown Norway rat yields insights into mammalian evolution , 2004, Nature.

[75]  M. Kasper,et al.  Early signs of lung fibrosis after in vitro treatment of rat lung slices with CdCl2 and TGF-β1 , 2004, Histochemistry and Cell Biology.

[76]  R. Kalluri,et al.  Epithelial-mesenchymal transition and its implications for fibrosis. , 2003, The Journal of clinical investigation.

[77]  C. Abbott,et al.  Fibroblast activation protein: A cell surface dipeptidyl peptidase and gelatinase expressed by stellate cells at the tissue remodelling interface in human cirrhosis , 1999, Hepatology.

[78]  T. Lee,et al.  Induction of pulmonary fibrosis in organ-cultured rat lung by cadmium chloride and transforming growth factor-beta1. , 1998, Toxicology.

[79]  A. Malmström,et al.  Alveolar accumulation of fibronectin and hyaluronan precedes bleomycin-induced pulmonary fibrosis in the rat. , 1992, The European respiratory journal.

[80]  R. Lundgren,et al.  Hyaluronan and type III procollagen peptide concentrations in bronchoalveolar lavage fluid in idiopathic pulmonary fibrosis. , 1989, Thorax.

[81]  H. Lan,et al.  Serum levels of WNT1-inducible signaling pathway protein-1 (WISP-1): a noninvasive biomarker of renal fibrosis in subjects with chronic kidney disease. , 2017, American journal of translational research.

[82]  Wujun Xiong,et al.  Wnt-induced secreted protein 1/CCN4 in liver fibrosis both in vitro and in vivo. , 2014, Clinical laboratory.

[83]  Geoffrey E. Hinton,et al.  Visualizing Data using t-SNE , 2008 .

[84]  J. Gauthier,et al.  Inhibition of TGF-beta signaling by an ALK5 inhibitor protects rats from dimethylnitrosamine-induced liver fibrosis. , 2005, British journal of pharmacology.

[85]  D. Sheppard.  Roles of alphav integrins in vascular biology and pulmonary pathology. , 2004, Current opinion in cell biology.